Status:
NOT_YET_RECRUITING
Asian Gynecological Brachytherapy Registry in Cervical Cancer
Lead Sponsor:
Tata Memorial Hospital
Collaborating Sponsors:
Chiang Mai University, Thailand
Mahidol University
Conditions:
Stage IIIA Cervical Cancer FIGO 2018
Stage IIIB Cervical Cancer FIGO 2018
Eligibility:
FEMALE
Brief Summary
Gynecological cancer poses as significant public health issue, especially in Asian countries, where it is a leading cause of cancer-related deaths among women. Cervical cancer accounts for around 311,...
Detailed Description
The registry will follow a retrospective cohort study design by including consecutive patients treated in participating institutions over a 12-month period. It encompasses patients receiving various l...
Eligibility Criteria
Inclusion
- Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype.
- Planned for treatment with definitive chemo-radiation and brachytherapy. (X- ray,CT, CT-Ultrasound or MRI based).
Exclusion
- Neuroendocrine cancer of the cervix or other rare histology subtypes.
- Patients with metastatic cervix cancer and not planned for radical doses of pelvic RT/brachytherapy may be excluded.
- Patients undergoing postoperative RT or RT for recurrent disease should be excluded.
Key Trial Info
Start Date :
January 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT07196033
Start Date
January 1 2026
End Date
May 1 2028
Last Update
September 29 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Tata Memorial Center
Mumbai, Maharashtra, India, 400012
2
Gunma University
Maebashi, Japan, Japan
3
Juntendo University
Tokyo, Japan, Japan
4
Mahidol University
Bangkok, Thailand, Thailand